GlucoWatch BlueCross BlueShield TEC Assessment Could Spur Adoption
This article was originally published in The Gray Sheet
CygnusGlucoWatch Biographer use in conjunction with standard blood glucose monitoring could result in fewer complications from severe diabetes, such as retinopathy and blindness, according to a recent study by the company
You may also be interested in...
Cygnus alleges it will suffer $450 mil. in damages and lose $1 bil. in potential revenue over the next 12 years if Sankyo Pharma ceases marketing and distribution of its GlucoWatch non-invasive glucose monitor
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.